SummaryRMgm-140
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 10587361 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | M. Yuda, Y. Chinzei |
Name Group/Department | Department of Medical Zoology |
Name Institute | School of Medicine, Mie University |
City | Tsu |
Country | Japan |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-140 |
Principal name | CTRP(-)1; CTRP(-)2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal numbers of ookinetes are produced (in vitro and in vivo in A. stephensi). Ookinetes do not show any morphological differences from wild-type parasites with Giemsa staining under microscopic observation. Ookinetes do not develop into oocysts. |
Oocyst | Normal numbers of ookinetes are produced. Ookinetes do not develop into oocysts. |
Sporozoite | Not tested |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation A P. falciparum mutant lacking CTRP (PFC0640w) has been generated which show a comparable defect in the formation of oocysts (Templeton, T.J. 2000. Mol. Microbiol. 36, 1-9). A mutant has been generated (RMgm-150) that expresses a mutated form of TRAP (thrombospondin-related anonymous protein; PB000374.03.0; PF13_0201), in which the cytoplasmic tail domain (CTD) of TRAP is replaced with the CTD domain of CTRP. The CTD of CTRP can complement the function of the CTD of TRAP, albeit not as well as TRAP as shown by the reduced invasion of salivary glands and hepatocytes. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0412900 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0315200 | ||||||||||||||||||||||||
Gene product | circumsporozoite- and TRAP-related protein | ||||||||||||||||||||||||
Gene product: Alternative name | CTRP | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | The DNA fragment containing the 5' portion of ctrp (2.05 kb) was subcloned into pBluescript II. The selectable marker gene pbdhfr was inserted into the MunI site of this fragment after ligation of EcoRI linkers to both ends. Integration of the construct results in disruption of the 5'-UTR region of ctrp. | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | pbdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The DNA fragment containing the 5' portion of ctrp (2.05 kb) was subcloned into pBluescript II. The selectable marker gene pbdhfr was inserted into the MunI site of this fragment after ligation of EcoRI linkers to both ends. Integration of the construct results in disruption of the 5'-UTR region of ctrp. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |